Navigation Links
Lung Cancer Alliance Salutes National Comprehensive Cancer Network (NCCN) for Its Lung Cancer Screening Guidelines
Date:10/28/2011

WASHINGTON, Oct. 28, 2011 /PRNewswire-USNewswire/ --Today Lung Cancer Alliance (LCA) hailed the leadership of the National Comprehensive Cancer Network (NCCN) for being the first professional society to recommend low-dose CT screening for high risk individuals and to develop comprehensive clinical practice guidelines on lung cancer screening.    

NCCN is a consortia of 21 of the world's leading cancer centers dedicated to improving the quality and effectiveness of care provided to patients with cancer.  

Released October 26, 2011, the NCCN guidelines stem from the landmark November 2010 decision by the National Cancer Institute (NCI) to halt its eight-year National Lung Screening Trial (NLST) because the study found  that screening people at high risk for lung cancer with low-dose (LDCT) scans reduced lung cancer mortality by 20%.

In the absence of screening, lung cancer is generally found after it has spread beyond the lung and existing treatments are rarely curative. Lung cancer alone accounts for close to one in three cancers deaths and is the leading cause of cancer death across the world.

"We appreciate NCCN's recognition of the urgency of the situation and working to allow the life-saving potential of CT screening to move swiftly and thoughtfully to clinical implementation." said Laurie Fenton Ambrose, LCA President & CEO.  As the leading national voice for patients and those at risk for lung cancer and as a consistent advocate for early detection and increased research funding for the disease, LCA will continue to work with respected professional societies to ensure the benefit of CT screening is  available to those at risk in a safe, efficient and equitable way."

The NCCN guidelines provide important clinical information on risk factors for lung cancer, criteria for selecting high-risk individuals for screening, recommendations for evaluation and follow-up of nodules found during screening,  accuracy of low-dose CT screening protocols and imaging modalities, and the benefits and risk of screening.

Fenton-Ambrose concluded, "This data from NCCN will serve as an important communications tool for physicians to discuss the risks as well as the recently documented significant benefits of this promising new lung cancer management approach."  

These recommendations and additional evolving information about lung cancer screening can be viewed at www.lungcanceralliance.org.  

Lung Cancer Alliance is the only national non-profit dedicated to providing support and advocacy for those living with or at risk for lung cancer.  LCA is committed to reversing decades of stigma and neglect by empowering those with or at risk for lung cancer, elevating awareness and changing health policy at both the federal and state level.

Follow Lung Cancer Alliance on Facebook: www.facebook.com/lungcanceralliance.  

Media Contact:

Kay Cofrancesco

kay@lungcanceralliance.org

202-742-1422


'/>"/>
SOURCE Lung Cancer Alliance
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ReportsnReports - Hyper Acute Pancreas (Pancreatic Cancer) - Analysis and Forecasts to 2020
2. ALIMTA First Chemotherapy Approved in Europe as Continuation Maintenance Therapy for Most Common Form of Lung Cancer
3. Groundbreaking Approach to Predicting Cancer Patients Response to Treatment Featured in Science Magazine
4. Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival
5. CDC Launches Effort to Protect Cancer Patients From Infections
6. Laparoscopic Surgeons Develop Fluorescent Light Technique to Improve Pancreatic Cancer Detection
7. Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011
8. Runners Take to the Streets in Undies to Fight Colon Cancer
9. HIFU All Hype? Understanding This Non-FDA-Approved Prostate Cancer Treatment
10. Advances in Radiotherapy Detailed at Cancer Summit Organized by Varian Medical Systems
11. Afinitor (Breast Cancer) - Analysis and Forecasts to 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017 Quest Diagnostics (NYSE: ... diagnostic information services, today announced that it has been ... 2017 by Fortune. The annual survey ... in the "Health Care: Pharmacy and Other Services" industry ... information services company to attain the designation. This is ...
(Date:2/16/2017)... 2017 The Lockwood Group (Lockwood), a medical communications ... Work in Connecticut list by the ... in a row that Lockwood has been in the top ... number-two spot in 2017. The award recognizes companies that have ... were determined through a survey conducted by The Best Companies ...
(Date:2/16/2017)... 16, 2017 Summary Provides understanding and ... the worlds leading healthcare companies. ... Description The Global Allergy Partnering Terms and Agreements ... agreements entered into by the world,s leading healthcare companies. ... value - Deals listed by company A-Z, industry sector, stage ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... Wells Pharmacy Network offers physicians ... controlled and non-controlled substances plus the ability to manage orders on their desktop ... now accept electronic prescriptions, according to the Office of the National Coordinator of ...
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective Action & Preventive ... FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... and preventive action (PA)? , The methods share techniques and tools but they ...
(Date:2/17/2017)... ... 2017 , ... MAP Revenue Cycle Solutions (MAP RCS), a ... promoted to Chief Executive Officer. , The need for maximizing reimbursements while ... demands the transition from pay-for-service to pay-for-performance models. By delivering efficient and effective ...
(Date:2/17/2017)... ... ... Like most hospitals across the nation, Onslow Memorial Hospital is looking for more ... Program (HRRP), the return of a patient to the hospital within 30 days of ... providers are struggling to leverage limited resources and technology, Onslow Memorial Hospital has saved ...
(Date:2/16/2017)... York (PRWEB) , ... February 17, 2017 , ... ... determination. After what took over 10 years of research, development and clinical trials, ... Technology™. NTX Technology™ is a patented compound of FDA approved ingredients that when ...
Breaking Medicine News(10 mins):